Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Sirion Therapeutics licenses U.S. rights to ophthalmic compound

July 26, 2006

Antiglaucoma agents revealed by French researchers

July 19, 2006

Alnylam amends RNAi collaboration agreements with Merck

July 10, 2006

NDA filing for T-Pred in inflammatory ocular conditions

July 7, 2006

Avastin studied in Australian trial for age-related macular degeneration

July 6, 2006

FDA approval for Lucentis

July 3, 2006

NDA submission for AzaSite in bacterial conjunctivitis

July 3, 2006

Macugen studied in phase IV maintenance trial

June 29, 2006

Lumigan approved for first-line use

June 26, 2006

rEV-131 studied in new trial for inflammation following cataract surgery

June 23, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
mRNA flu vaccine can activate broad germinal center response
BioWorld
On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...